Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Pfizer, Bayer to Pull Plug on “G1” Products with High Generic Erosions
Pfizer Japan and Bayer Yakuhin are set to become the first innovative drug makers to pull their established off-patent products from the market under the so-called “G1” withdrawal scheme due to high generic penetrations, the health ministry revealed. Pfizer plans…
To read the full story
Related Article
- Lilly’s Gemzar to Exit Japan Market Next Spring under G1 Withdrawal Rule
May 13, 2024
- Only 4 “G1” LLPs to Make Exit, 62 to Get Generic Prices in 2024 as Withdrawal Scheme Hits Snag
August 23, 2023
- MHLW Announces New Drug Prices for 1st Off-Year Revision in April
March 5, 2021
- MHLW Reveals Details of New Withdrawal Rules for Off-Patent Branded Drugs
April 1, 2019
REGULATORY
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…